"Our goal of identifying and developing transformative medicines to treat diseases with unmet need can only be achieved through rigorous science and deep collaboration among truly gifted people."
I joined Genentech in 2006 after seven years in the Boston biotech sector, four of which were spent in a productive collaboration with scientists here at Genentech. The decision to become an East Coast transplant was driven by my passion to take small molecule drugs from concept to patients, and to do so in an environment driven by science and the desire to have a dramatic impact on patient outcome.
Nat Med. 2015; 21(5):431-9.
As a transition point between the bench and the clinic, the translational oncology group is focused on providing data that determines the relative efficacy of potential agents and correlates efficacy with target inhibition and drug exposures to help inform clinical strategy. We work closely with our discovery colleagues in Cancer Immunology and Molecular Oncology to identify ways to combine our drugs to combat drug resistance.
Embedded within the translational group we also have laboratories dedicated to developing tumor specific antibodies conjugated to a variety of drug payloads targeting key vulnerabilities within the cancer cells. We are also focused on developing a class of bi-specific antibodies that can redirect T-cells, and other immune cells, to selectively target tumors.